Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects
- PMID: 3207553
- PMCID: PMC1386524
- DOI: 10.1111/j.1365-2125.1988.tb03383.x
Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects
Abstract
1. Delayed-release mesalazine has been formulated to deliver 5-aminosalicylic acid to the colon. We have therefore studied the ileostomy excretion and coat dissolution of this preparation. 2. Following ingestion of a single tablet 88% (range 69-114%) of the 400 mg dose appeared unchanged in the ileosomy effluent over the subsequent 12 h. 3. Ileostomy effluent pH appeared to be a major determinant of 5-aminosalicylic acid release. 4. In vitro studies revealed rapid coat dissolution above pH 7.0, slow dissolution between pH 6.0 and 7.0 and non-dissolution at pH 2.0 and 4.0.
Similar articles
-
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs. 1989 Oct;38(4):500-23. doi: 10.2165/00003495-198938040-00003. Drugs. 1989. PMID: 2684592 Review.
-
5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.Gastroenterology. 1982 Nov;83(5):1062-70. Gastroenterology. 1982. PMID: 7117789
-
Mesalazine release from coated tablets: effect of dietary fibre.Br J Clin Pharmacol. 1991 Aug;32(2):248-50. doi: 10.1111/j.1365-2125.1991.tb03891.x. Br J Clin Pharmacol. 1991. PMID: 1657094 Free PMC article.
-
Dissolution profiles of mesalazine formulations in vitro.Pharm Weekbl Sci. 1990 Oct 19;12(5):200-4. doi: 10.1007/BF01980047. Pharm Weekbl Sci. 1990. PMID: 2255590
-
Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.Drugs. 1989 Jan;37(1):73-86. doi: 10.2165/00003495-198937010-00005. Drugs. 1989. PMID: 2651087 Review.
Cited by
-
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002. Clin Pharmacokinet. 1990. PMID: 2199130 Review.
-
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs. 1989 Oct;38(4):500-23. doi: 10.2165/00003495-198938040-00003. Drugs. 1989. PMID: 2684592 Review.
-
Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).Br J Clin Pharmacol. 1992 Feb;33(2):179-82. doi: 10.1111/j.1365-2125.1992.tb04021.x. Br J Clin Pharmacol. 1992. PMID: 1550697 Free PMC article. Clinical Trial.
-
Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.Drugs R D. 2016 Mar;16(1):35-43. doi: 10.1007/s40268-015-0113-9. Drugs R D. 2016. PMID: 26883035 Free PMC article.
-
Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.Br J Clin Pharmacol. 1998 Aug;46(2):173-5. doi: 10.1046/j.1365-2125.1998.00762.x. Br J Clin Pharmacol. 1998. PMID: 9723828 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources